Short Interest in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) Drops By 12.9%

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totalling 1,196,704 shares, a drop of 12.9% from the August 15th total of 1,373,756 shares. Based on an average daily trading volume, of 31,135 shares, the short-interest ratio is currently 38.4 days. Approximately 2.8% of the shares of the company are short sold.

Shares of ZOM traded down $0.02 during trading hours on Friday, reaching $1.77. 8,203 shares of the company traded hands, compared to its average volume of 51,785. Zomedica Pharmaceuticals Corp has a 12 month low of $1.75 and a 12 month high of $2.98.

Zomedica Pharmaceuticals Corp (NYSEAMERICAN) (NYSE:ZOM) last announced its earnings results on Thursday, August 9th. The company reported ($0.04) earnings per share for the quarter.

In other news, Director James Lebar sold 200,000 shares of the firm’s stock in a transaction on Tuesday, August 28th. The shares were sold at an average price of $2.15, for a total transaction of $430,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 57.28% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Northern Trust Corp bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth about $144,000. Bank of New York Mellon Corp bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth about $160,000. Schwab Charles Investment Management Inc. bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth about $167,000. BlackRock Inc. bought a new stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) during the second quarter worth about $3,553,000. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Zomedica Pharmaceuticals Corp (NYSEAMERICAN) by 6,107.1% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 12,079,080 shares of the company’s stock worth $27,178,000 after acquiring an additional 11,884,480 shares in the last quarter. 15.83% of the stock is currently owned by hedge funds and other institutional investors.

About Zomedica Pharmaceuticals Corp (NYSEAMERICAN)

Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs.

See Also: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica Pharmaceuticals Corp (NYSEAMERICAN) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply